Montelair (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from causing bronchoconstriction, airway edema, and inflammatory cell recruitment, which together improve breathing and reduce allergic inflammation.

The specific dose of Montelair is determined by the prescribing clinician based on the patient’s age, condition, and response. Typical adult and pediatric regimens are outlined in the product label, but the prescriber sets the exact regimen.

Safety data for montelukast in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Montelair, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelair (montelukast) offers an oral alternative to inhaled corticosteroids and provides additional benefit for patients with allergic rhinitis or exercise‑induced bronchoconstriction. Compared with other leukotriene antagonists such as zafirlukast, montelukast has a once‑daily dosing schedule and a broader safety profile, though individual response varies.

Montelair tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Montelair is taken orally as a tablet, usually once daily in the evening. It can be swallowed with or without food, but consistent timing each day helps maintain steady drug levels.

Serious adverse events, although rare, include angioedema, severe skin reactions such as Stevens‑Johnson syndrome, eosinophilic granulomatosis with polyangiitis, hepatic injury, and neuropsychiatric effects like depression or suicidal thoughts. Patients should seek immediate medical attention if any of these occur.

Montelair is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. Caution is also advised for patients with severe hepatic impairment or those taking interacting medicines that could significantly alter drug levels.